Industry Response Time Is Contributing To Slower Drug Approvals, FDA Says
• By The Pink Sheet
Industry response time is contributing to the increase in FDA drug approval times, Office of Review Management Special Assistant to the Director Kim Colangelo told the Regulatory Affairs Professionals Society's annual conference in Baltimore Nov. 7
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
